The Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease
NurOwn is the clearest test yet of how far the agency may be willing to bend to approve a new medicine for a rare and deadly condition with few treatment options.
The meeting was scheduled after ALS advocates delivered a 30,000-signature petition seeking a public vetting of the treatment. "The amazing testimonials we have seen online do not align with the data that Brainstorm has shared," the group said in a statement. NurOwn is made from stem cells collected from patients' bone marrow. The cells are processed in a lab with biological proteins designed to promote nerve growth, and then injected into the spinal column.
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA skeptical of experimental ALS treatment pushed by patient advocatesThe Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease.
Read more »
FDA skeptical of experimental ALS treatment pushed by patient advocatesThe Food and Drug Administration meets this week to consider a much-debated treatment for Lou Gehrig’s disease.
Read more »
Some cold medicines might not work according to FDAThe drug is known as phenylephrine. It’s found in medicine you probably have at home, like Dayquil and Mucinex.
Read more »
Coherus BioSciences’ new injector treatment for cancer patients rejected by FDACoherus BioSciences said Monday that the U.S. Food and Drug Administration rejected its regulatory submission for a new on-body injector form of Udenyca, a...
Read more »
Latin American Heritage Festival in Birmingham celebrates music, food, cultureThe Saturday event at Birmingham Museum of Art was organized as part of National Hispanic Heritage Month.
Read more »
Les Turner ALS Walk for Life raises money to change outcomes for people living with diseaseABC7's Phil Schwarz has been a supporter of the organization for years, and interviewed the new CEO, Laura Freveletti.
Read more »